About Rayaldee
Dosing for Rayaldee
Rayaldee offers once-daily dosing.1
Before starting treatment, ensure that serum calcium is <9.8 mg/dL.1
The starting dosage of Rayaldee is 30 mcg administered orally once daily at bedtime.1
Dosage may be increased to 60 mcg if, after approximately 3 months, intact parathyroid hormone (iPTH) levels remain above the desired therapeutic range.1
Instruct patients to swallow Rayaldee capsules whole.1
The starting dosage of Rayaldee is 30 mcg administered orally once daily at bedtime.1
Dosage may be increased to 60 mcg if, after approximately 3 months, intact parathyroid hormone (iPTH) levels remain above the desired therapeutic range.1
Instruct patients to swallow Rayaldee capsules whole.1
Monitoring serum levels and titrating dosage
The maintenance dosage of Rayaldee should target serum levels of1
The maintenance dosage of Rayaldee should target serum levels of1
| • | Total 25-hydroxyvitamin D [25(OH)D] between 30 and 100 ng/mL |
| • | Intact parathyroid hormone (iPTH) within the desired therapeutic range |
| • | Calcium levels (corrected for low albumin) within the normal range |
| • | Phosphorus levels <5.5 mg/dL |
Rayaldee takes a dual-action approach to treating SHPT1
Rayaldee® (calcifediol) extended-release capsules offers a dual-action approach by gradually raising 25-hydroxyvitamin D [25(OH)D] and lowering intact parathyroid hormone (iPTH) levels in adults with secondary hyperparathyroidism (SHPT) and stage 3 or 4 chronic kidney disease (CKD) and insufficient vitamin D levels.1,2,4
Watch this video to see how the gradual, progressive metabolism of Rayaldee leads to decreased iPTH.1,3,4 |
The faces of SHPT
Select a patient to get the whole picture
Stacy is a proud grandmother of newborn twins. You have recently diagnosed SHPT. You are looking for a proactive treatment that will help optimally manage her 25(OH)D and iPTH levels early on and into the later stages of CKD (3 & 4).
Actor portrayal does not represent real patient.
| CKD 3A | 25(OH)D 10 ng/mL |
| iPTH 188 pg/mL | Ca 9.6 mg/dL |
Do you see patients like Stacy in your practice?
Learn how Rayaldee may help
Gina has entered retirement and is excited to start this new stage in her life. You’re happy for her but concerned because her iPTH level is heading in the wrong direction despite her taking nutritional vitamin D. You are frustrated with the lack of control and want to consider different options.
Actor portrayal does not represent real patient.
| CKD 3B | 25(OH)D 22 ng/mL |
| iPTH 139 pg/mL | Ca 9.4 mg/dL |
Do you see patients like Gina in your practice?
Learn how Rayaldee may help
Harold has been taking active vitamin D for a while now, and you are noticing that his iPTH level is still rising and his 25(OH)D level is low. In addition, you are concerned about the risk of hypercalcemia associated with active vitamin D use and think it may be time for a switch.
Actor portrayal does not represent real patient.
| CKD 4 | 25(OH)D 17 ng/mL |
| iPTH 209 pg/mL | Ca 9.7 mg/dL |
Do you see patients like Harold in your practice?
Learn how Rayaldee may help*Not actual patient
References: 1. Rayaldee [package insert]. Miami, FL: OPKO Pharmaceuticals, LLC; December 2019. 2. Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44(4):316-325. 3. Sprague SM, Strugnell SA, Bishop CW. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert Rev Endocrinol Metab. 2017;12(5):289-301. 4. Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol. 2012(2);7:358-365.